Lipella presents positive Phase 2a data for LP-310; 0.50mg dose shows stat-sig efficacy in OLP

LIPELLA PHARMACEUTICALS INC.

Statistically significant improvements at 0.50mg dose: IGA from 3.42 to 1.71 (p=0.007), REU from 26.91 to 11.88 (p=0.003).
OLP Symptom Severity Measure dropped from 14.92 to 4.88 (p=0.003); Pain NRS from 6.42 to 2.25 (p=0.003).
No treatment-related serious adverse events, no discontinuations, and no detectable systemic tacrolimus levels.
Data from 0.25mg and 0.50mg cohorts presented at 2025 AAOM/EAOM meeting; final topline data from fully enrolled trial expected Q2 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.